Adial Pharmaceuticals (ADIL) vs BioVie (BIVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioVie (BIVI) has outperformed Adial Pharmaceuticals (ADIL) over the past year, losing 35.0% versus a loss of 60.3%. Over five years, BIVI leads with a -99.8% price change compared with -99.8% for ADIL. BioVie is the larger company by market cap ($11.1 million vs $10.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADIL | BIVI |
|---|---|---|
| Share price | $3.97 | $1.28 |
| Market cap | $10.42M | $11.11M |
| 1-day change | -0.50% | -8.57% |
| YTD return | -27.82% | +10.34% |
| 1-year return | -60.30% | -35.03% |
| 5-year return | -99.84% | -99.78% |
| EPS (TTM) | $-20.65 | $-3.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.50 | $3.79 |
| 52-week low | $1.31 | $0.82 |
| Distance from 52-week high | -62.19% | -66.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +109.82% | +310.94% |
| Average volume | 56.16K | 4.60M |
| Shares outstanding | 2.63M | 8.68M |
| Employees | 5 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed ADIL by 25.3 percentage points over the past year.
About Adial Pharmaceuticals
ADIL stock →Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
Healthcare · Biotechnology · 5 employees
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Healthcare · Biotechnology · 13 employees
ADIL vs BIVI FAQ
Which is bigger, Adial Pharmaceuticals or BioVie?
BioVie (BIVI) is larger, with a market capitalization of $11.11M compared with $10.42M for Adial Pharmaceuticals (ADIL).
Which stock has performed better over the past year, ADIL or BIVI?
BIVI returned -35.03% over the past 12 months, compared with -60.30% for ADIL (price return, excluding dividends). Past performance does not predict future results.
Are Adial Pharmaceuticals and BioVie in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.